Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with the landmark FDA approval of its innovative drug, MIPLYFFA, for the treatment of Niemann-Pick disease type C. This regulatory milestone not only offers new hope for patients afflicted with this ultra-rare and progressive neurodegenerative disorder but has also driven Zevra's shares to a new 52-week high.
In addition to ZVRA, several other stocks highlighted on our site also reached new 52-week highs yesterday.
*Note: Last Closing Price refers to the stock's price at the close of trading on September 20, 2024.
**Related Reading**
"EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot?"